Cerity Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,067 shares of the specialty pharmaceutical company’s stock, valued at approximately $431,000.
Several other institutional investors have also recently added to or reduced their stakes in the business. Burney Co. lifted its stake in Supernus Pharmaceuticals by 0.6% during the first quarter. Burney Co. now owns 62,872 shares of the specialty pharmaceutical company’s stock worth $2,278,000 after purchasing an additional 357 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in Supernus Pharmaceuticals by 41.6% during the third quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 368 shares during the period. Amalgamated Bank increased its holdings in shares of Supernus Pharmaceuticals by 1.8% in the fourth quarter. Amalgamated Bank now owns 24,053 shares of the specialty pharmaceutical company’s stock valued at $858,000 after purchasing an additional 416 shares during the period. Mercer Global Advisors Inc. ADV increased its holdings in shares of Supernus Pharmaceuticals by 4.2% in the third quarter. Mercer Global Advisors Inc. ADV now owns 12,724 shares of the specialty pharmaceutical company’s stock valued at $431,000 after purchasing an additional 510 shares during the period. Finally, Assetmark Inc. increased its holdings in shares of Supernus Pharmaceuticals by 2.3% in the fourth quarter. Assetmark Inc. now owns 24,570 shares of the specialty pharmaceutical company’s stock valued at $876,000 after purchasing an additional 558 shares during the period.
Supernus Pharmaceuticals Price Performance
Shares of SUPN stock opened at $31.67 on Thursday. The business’s fifty day moving average price is $30.96 and its 200 day moving average price is $34.08. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.06 and a 1-year high of $42.09. The firm has a market capitalization of $1.73 billion, a PE ratio of 43.38 and a beta of 1.02.
Wall Street Analyst Weigh In
SUPN has been the topic of a number of recent research reports. Piper Sandler dropped their target price on Supernus Pharmaceuticals from $46.00 to $43.00 in a report on Wednesday, July 26th. StockNews.com lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. Finally, TheStreet lowered Supernus Pharmaceuticals from a “b+” rating to a “c+” rating in a report on Friday, May 12th.
Get Our Latest Report on Supernus Pharmaceuticals
Insider Buying and Selling
In related news, VP Tami Tillotson Martin sold 8,100 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $32.00, for a total transaction of $259,200.00. Following the transaction, the vice president now owns 85,249 shares of the company’s stock, valued at $2,727,968. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.76% of the stock is currently owned by corporate insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Recommended Stories
- Five stocks we like better than Supernus Pharmaceuticals
- How to Calculate Return on Investment (ROI)
- These Quality Dividend Kings Grow their Dividends the Fastest
- What Are Dividend Achievers? An Introduction
- 3 Growth Stocks to Buy in September
- How to Invest in the Entertainment Industry
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
